Renalytix plc

("Renalytix" or the "Company")

Publication of Annual Report 2022

and Notice of 2022 Annual General Meeting

LONDON and SALT LAKE CITY, UT November 10, 2022 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that the Annual Report for the year ended 30 June 2022 and the Notice of the 2022 Annual General Meeting ('AGM') have now been published on the Company's website in accordance with AIM Rule 20:  

https://investors.renalytix.com/news-and-events/documents-and-presentations

The 2022 Annual Report and the Notice of AGM will be posted to shareholders who have not consented to receive electronic communications.

The AGM will be held in-person on 19 December 2022 at 11.00 a.m. (GMT) at 6 Stratton Street Mayfair, London W1J 8LD.

To help with practical arrangements for the AGM, any Shareholder wishing to attend is requested to register first by contacting Walbrook PR via email at renalytix@walbrookpr.com or by telephone at +44 (0)20 7933 8790.

For further information, please contact:

About Kidney Disease

Kidney disease is a public health epidemic affecting over 850 million people globally.² The Centers for Disease Control and Prevention estimates that 15% of U.S. adults, or over 37 million people³, have chronic kidney disease (CKD). Nearly 95% of people with CKD are in early stages 1-3⁴. Despite its magnitude, early-stage (1-3) CKD is underdiagnosed and undertreated, largely because it's asymptomatic at this time in the disease. As many as 9 in 10 adults with CKD, and 2 in 5 adults with severe CKD do not know they have the condition.³

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis^TM for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory-developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D with early CKD stages 1-3. We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit  www.renalytix.com.

About KidneyIntelX^TM

KidneyIntelXTM is a laboratory-developed test demonstrated to be a reliable, bioprognosticTM methodology that yields a simple-to-understand, custom risk score, enabling prediction of which adult patients with T2D and early CKD (stages 1-3) are at low, intermediate or high risk for rapid progressive decline in kidney function. By combining information from KidneyIntelX with newer cardio- and reno-protective therapies, doctors will have more information in determining which patients are at higher versus lower risk for rapid disease progression and may be able to more appropriately target resources and guideline-recommended treatments to advance kidney health. KidneyIntelX is supported by a growing body of clinical, utility and health economic studies (including a validation study of two large cohorts) and has a demonstrated a 72% improvement in predicting those patients who are at high risk for rapid progressive decline in kidney function versus the current standard of care (eGFR and UACR). KidneyIntelX has also received Breakthrough Device Designation from the U.S. Food and Drug Administration and has submitted for De Novo marketing authorization. To learn more about KidneyIntelX and review the evidence, visit  www.kidneyintelx.com.